ALR Technologies, Inc.’s stock is currently trading at $0.21, up 425%, on massive volume of 3.3+ million traded shares. Earlier this month, QualityStocks highlighted the company in its daily newsletter when the stock was trading for only $0.04 and largely ignored by the investment community. To sign up for the newsletter, visit www.signup.qualitystocks.net.

Today, ALR Technologies announced that the US Patent and Trademark Office has approved its patent application regarding patient compliance and remote monitoring of patient’s use of nebulizer compressors. This approval protects the company’s Health-E-Connect health management communications system and, more importantly, grants ALRT the exclusive ability to remotely monitor the use of nebulizer compressors in the delivery of medications to patients with COPD, chronic asthma and cystic fibrosis.

With more than 750,000 investors signed up for the QualityStocks Daily Newsletter, it is no wonder that highly successful stock picks are made regularly. Using a proprietary data management system,

QuantRx Biomedical Corp., a diagnostic company focused on developing and commercializing innovative diagnostic products, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent extending its lateral flow testing intellectual property suite. This new patent will add significant protection as QuantRx enters the market with its hypersensitive point-of-care lateral flow based system. Together with the patented Q-reader technology, QuantRx is able to provide CLIA (Clinical Laboratory Improvement Amendments) waived Point-of-Care (POC) tests that other technologies cannot offer.

“This milestone event for QuantRx marks the culmination of over a decade of research by our exceptional R&D team,” stated Dr. William Fleming, President of Diagnostics at QuantRx. “RapidSense® with its exceptional low level sensitivity, coupled with our unique device technology, allows QuantRx to capitalize on its knowledge base to create tests that, until now, have been limited to laboratory or simple qualitative testing. QuantRx believes that it

Unigene Laboratories, Inc. reported the issue of its first patent for its Site-Directed Bone Growth (SDBG). The technology is designed to facilitate and accelerate bone growth at targeted locations using a minimally invasive procedure that can be performed on an outpatient basis. Animal studies have shown that SDBG can grow significant amounts of high quality bone.

U.S patent #7, 531, 518, “Method of Fostering Bone Formation and Preservation,” claims to provide broad protection for the inducement of rapid bone growth and its subsequent preservation using a variety of therapeutic agents, including parathyroid hormone, calcitonin and bisphosphonates. The U.S. Patent and Trademark Office are currently reviewing several other patent applications relative to the SDBG program.

“The issuance of this first patent provides us with broad intellectual property protection for this novel technology,” stated Dr. Warren Levy, President and CEO of Unigene. “This patent and the potential issuance of other patent applications could provide

Osteologix, Inc. announced this morning that is has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application titled “Water-Soluble Strontium Salts for Use in Treatment of Cartilage and/or Bone Conditions.” The reported allowance of claims covers the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the company’s lead osteoporosis drug candidate.

The company anticipates that the patent will be issued in the second half of 2009. According to the press release, the patent’s 20-year term would expire in 2024. Additionally, the company has a number of other pending patent applications covering various aspects of the NB S101 drug program including composition, manufacturing and method of use patent applications.

“Based on the Notice of Allowance and the claims allowed by the USPTO, we believe the intellectual property protections established by this US patent allowance, coupled with our recently

CNS Response, Inc. announced that it has received a patent from the U.S. Patent and Trademark Office. The patent, numbered 7,489,964 and titled “Electroencephalography Based Systems and Methods for Selecting Therapies and Predicting Outcomes”, extends application of rEEG® technology to novel methods that can expand indications for CNS pharmaceuticals.

“One of the most compelling opportunities in pharmaceutical marketing is the ability to expand new indications for already approved medications,” commented CNS Response CEO Len Brandt. “With the successful completion of our multisite study for the treatment of resistant depression, I believe we will have demonstrated the utility of the rEEG technology not only to physicians treating behavioral illness, but also to the pharmaceutical industry including ways described in this patent.”

The awarded patent presents novel use of CNS Response protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG computer analysis. One demonstration of patient

Today, TeleCommunication Systems, Inc. announced that the U.S. Patent and Trademark Office has granted the company patent number 7,483,983 for “Method and System for Deploying Content to Wireless Devices.” This invention allows internet content to be displayed on wireless devices through web browser applications.

The Nielsen Company recently reported the results of a survey that found 17 percent of U.S. mobile phone users, or 43 million subscribers, access the Internet. Although these users are able to access internet content through the web browser of their wireless device, most internet sites are only designed to display information on a standard computer screen — not on small mobile screens. Additionally, wireless devices that access the internet use different mobile browsers and protocols, making it difficult for providers to consistently deliver content across a wide range of wireless devices.

TeleCommunication’s invention, however, allows internet content to be displayed in a variety of formats, dynamic

eFoodSafety.com (EFSF) is a developer of nutraceutical products to help improve an array of health conditions for consumers. Nutraceutical products are defined by their combination of natural foods and supplements and the market for such products is estimated to reach $845 billion by 2015.

eFoodSafety’s products focus on wellness issues including lowered cholesterol, boosted metabolism, acne prevention and scarring reduction. The company’s Cinnergen product, which is used to provide nutrients to metabolize blood sugar, is currently available in major retailers such as GNC, Rite Aid and Vitamin Shoppe.

The Arizona-based company’s Cinnechol product is used to naturally treat cholesterol problems and competes in a $20-billion market. eFoodSafety is also working on products to treat skin problems, including acne, and staph infections and viruses. The company’s popular Boost Bar is used by health-conscious consumers to boost their immune systems. In June, the company said its OraPhyt product, which is used

Visicu (EICU) continued its history of posting strong operating results, posting second quarter results on Thursday with in-line revenues of $9.1 million